A biomarker is, according to the US National Institutes of Health, ?a characteristic that is objectively measured and evaluated as an indicator of normal biological processes, pathogenic processes, or pharmacologic responses to a therapeutic intervention.?
Biomarkers make take the form of cellular characteristics, metabolites (e.g. sugars, lipids and hormones), molecular variations, or physical features (e.g., clinical symptoms) and are assessed accordingly, via measurement, annotation, documents, and images.
Increasingly, the discovery of novel biomarkers is closely associated with the advances in molecular biology techniques that can be accessed through analysis of DNA, RNA or proteins.
We can discriminate four main types of molecular biomarkers-
? Genomic biomarkers- Based on the analysis of DNA (deoxyribonucleic acid) profiles, especially the analysis of SNPs (single nucleotide polymorphisms), i.e. identification of punctual variations in genomic DNA.
? Transcriptomic biomarkers- Base on the analysis of RNA expression profiles.
? Proteomic biomarkers- Base on the analysis of the protein profiles.
? Metabolomic biomarkers- Base on the analysis of metabolites (metabolites are the intermediates and products of metabolism).
Commercializing biomarkers is the path that a biomarker could be used in therapeutic or diagnostic. In this report mainly covers consumables, services, software of this market.
In the last several years, global market of Commercializing Biomarkers in Therapeutic and Diagnostic Applications developed rapidly, with an average growth rate of 8.49%. In 2015, the consumables revenue growth rate was about 8.5%, the services revenue growth rate was nearly 8.6%, and the consumables revenue growth rate was the highest among the Commercializing Biomarkers in Therapeutic and Diagnostic Applications Industry.
North America is the largest consumer of Commercializing Biomarkers, with the sales market share nearly 42%.
The second place is Europe, following North America with the sales market share of 31%. Japan and China is also the important market, with the total sales marker share of 18.6%.
According to this study, over the next five years the Commercializing Biomarkers in Therapeutic and Diagnostic Applications market will register a 6.1% CAGR in terms of revenue, the global market size will reach USD 24400 million by 2024, from USD 17200 million in 2019. In particular, this report presents the global market share (sales and revenue) of key companies in Commercializing Biomarkers in Therapeutic and Diagnostic Applications business, shared in Chapter 3.
This report presents a comprehensive overview, market shares, and growth opportunities of Commercializing Biomarkers in Therapeutic and Diagnostic Applications market by product type, application, key manufacturers and key regions and countries.
This study considers the Commercializing Biomarkers in Therapeutic and Diagnostic Applications value and volume generated from the sales of the following segments-
Segmentation by product type- breakdown data from 2014 to 2019, in Section 2.3; and forecast to 2024 in section 11.7.
Consumables
Services
Software
Segmentation by application- breakdown data from 2014 to 2019, in Section 2.4; and forecast to 2024 in section 11.8.
Oncology
Cardiology
Neurology
Other
This report also splits the market by region- Breakdown data in Chapter 4, 5, 6, 7 and 8.
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Spain
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries
The report also presents the market competition landscape and a corresponding detailed analysis of the major vendor/manufacturers in the market. The key manufacturers covered in this report- Breakdown data in in Chapter 3.
Roche
Dako (Agilent Technologies)
Merck
BD
Abbott
Genesys Biolabs (20/20GeneSystems)
Affymetrix
Agendia
ALMAC
Arrayit
Biocartic
BG Medicine
KEGG EXPRESSION Database
Thermo Fisher
BGI
In addition, this report discusses the key drivers influencing market growth, opportunities, the challenges and the risks faced by key manufacturers and the market as a whole. It also analyzes key emerging trends and their impact on present and future development.
Research objectives
To study and analyze the global Commercializing Biomarkers in Therapeutic and Diagnostic Applications consumption (value & volume) by key regions/countries, product type and application, history data from 2014 to 2018, and forecast to 2024.
To understand the structure of Commercializing Biomarkers in Therapeutic and Diagnostic Applications market by identifying its various subsegments.
Focuses on the key global Commercializing Biomarkers in Therapeutic and Diagnostic Applications manufacturers, to define, describe and analyze the sales volume, value, market share, market competition landscape, SWOT analysis and development plans in next few years.
To analyze the Commercializing Biomarkers in Therapeutic and Diagnostic Applications with respect to individual growth trends, future prospects, and their contribution to the total market.
To share detailed information about the key factors influencing the growth of the market (growth potential, opportunities, drivers, industry-specific challenges and risks).
To project the consumption of Commercializing Biomarkers in Therapeutic and Diagnostic Applications submarkets, with respect to key regions (along with their respective key countries).
To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.
To strategically profile the key players and comprehensively analyze their growth strategies.
